Biocept Stock Today
| BIOCQ Stock | 0.0001 0.00 0.00% |
PerformanceFair
| Odds Of DistressStrong
|
Biocept is selling at 1.0E-4 as of the 16th of January 2026; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 1.0E-4. Biocept has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 25th of June 2024 and ending today, the 16th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of February 2005 | Category Healthcare | Classification Health Care |
Biocept is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 2.63 M outstanding shares of which 15 K shares are currently shorted by private and institutional investors with about 0.05 days to cover all short positions. More on Biocept
Moving against Biocept Stock
| 0.34 | GE | GE Aerospace Earnings Call This Week | PairCorr |
| 0.32 | DIS | Walt Disney Sell-off Trend | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Biocept Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsBiocept can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biocept's financial leverage. It provides some insight into what part of Biocept's total assets is financed by creditors.
| |||||
Biocept (BIOCQ) is traded on NASDAQ Exchange in USA and employs 50 people. Biocept is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 262. Biocept classifies itself under Biotechnology sector and is part of Health Care industry. The entity has 2.63 M outstanding shares of which 15 K shares are currently shorted by private and institutional investors with about 0.05 days to cover all short positions.
Biocept generates negative cash flow from operations
Check Biocept Probability Of Bankruptcy
Biocept Historical Income Statement
Biocept Stock Against Markets
Biocept Corporate Executives
Elected by the shareholders, the Biocept's board of directors comprises two types of representatives: Biocept inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biocept. The board's role is to monitor Biocept's management team and ensure that shareholders' interests are well served. Biocept's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biocept's outside directors are responsible for providing unbiased perspectives on the board's policies.
Additional Tools for Biocept Stock Analysis
When running Biocept's price analysis, check to measure Biocept's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocept is operating at the current time. Most of Biocept's value examination focuses on studying past and present price action to predict the probability of Biocept's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocept's price. Additionally, you may evaluate how the addition of Biocept to your portfolios can decrease your overall portfolio volatility.